JSJunfei Shao

Junfei Shao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junfei Shao has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Ji

    Department of Neurosurgery, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China

    6 shared publications
  • Jiantong Jiao

    Department of Neurosurgery, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China

    5 shared publications
  • Jiantong Jiao

    Department of Neurosurgery, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China

    4 shared publications
  • Wei Ji

    Department of Neurosurgery, Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, China

    4 shared publications
  • Bin Xu

    Department of Neurosurgery, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China

    3 shared publications
  • Bin Xu

    Department of Neurosurgery, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China

    3 shared publications

Latest Publications

  • Open Access

    Complete Surgical Resection of a C3 Neuroenteric Cyst With Concurrent Cervical Fusion Deformity Through Posterior Midline Approach in the Lateral Position: Case Report

    by Jin Huang, Yuning Chen, Kefei Chen, Wei Ji, Junfei Shao, Jian Guan

    BACKGROUND AND IMPORTANCE: Enterogenic cysts often occur along the spinal axis and are frequently associated with congenital spinal malformations. The special location of the lesion can limit the surgical resection to achieve complete removal. In this report, the authors describe a successful case of complete resection of a ventral enterogenic cyst in the cervical spinal cord using a posterior midline approach in the lateral position.CLINICAL PRESENTATION: This report discusses a case of a 36-year-old young female patient who presented with relatively short-term discomfort and pain in the left shoulder and neck area. MRI examination revealed a cystic mass located ventrally in the C3 cervical spinal cord. We performed a posterior surgical approach and, under the lateral position, the lesion was completely resected. The surgical treatment alleviated the neurological dysfunction. During the follow-up periods of 3 and 6 months, the patient recovered well, and magnetic resonance imaging scans showed no residual lesion.CONCLUSION: Complete surgical resection of the cyst wall is the only effective treatment for enterogenic cysts because partial resection or subtotal resection may lead to recurrence. For patients with concomitant spinal malformations, a posterior midline approach in the lateral position is a viable surgical option.


  • Open Access

    A novel ARHGAP family gene signature for survival prediction in glioma patients

    by Jin Huang, Gaosong Wang, Jiahao Zhang, Yuankun Liu, Yifan Shen, Gengjing Chen, Wei Ji, Junfei Shao

    ARHGAP family genes are often used as glioma oncogenic factors, and their mechanism of action remains unexplained. Our research entailed a thorough examination of the immune microenvironment and enrichment pathways across various glioma subtypes. A distinctive 6‐gene signature was developed employing the CGGA cohort, leading to insights into the disparities in clinical characteristics, mutation patterns, and immune cell infiltration among distinct risk categories. Additionally, a unique nomogram was established, grounded on ARHGAPs, with DCA curves illustrating the model's prospective clinical utility in guiding therapeutic strategies. Emphasizing the role of ARHGAP30, integral to our model, its impact on glioma severity and the credibility of our risk assessment model were substantiated through RT‐qPCR, Western blot analysis, and cellular functional assays. We identified 6 ARHGAP family genes associated with glioma prognosis. Analysis using the Kaplan–Meier method indicated a correlation between elevated risk levels and adverse outcomes in glioma patients. The risk score, linked with tumour staging and IDH mutation status, emerged as an independent factor predicting prognosis. Patients in the high‐risk category exhibited increased immune cell infiltration, enhanced tumour mutational burden, more pronounced expression of immune checkpoint genes, and a better response to ICB therapy. A nomogram, integrating the risk score with the pathological features of glioma patients, was developed. DCA analysis and cellular studies confirmed the model's potential to improve clinical treatment outcomes for patients. A novel ARHGAP family gene signature reveals the prognosis of glioma.


  • Open Access

    The Expression Profiles and Clinical Significance of Mixed Lineage Kinases in Glioma

    by Jin Huang, Yuankun Liu, Gaosong Wang, Yuning Chen, Yifan Shen, Jiahao Zhang, Wei Ji, Junfei Shao

    Mixed lineage kinases (MLKs), comprising seven members: MLK1‐4, dual leucine zipper kinase (DLK), leucine zipper kinase (LZK), and sterile alpha motif and leucine zipper containing kinase (ZAK), belong to the mitogen‐activated protein kinase kinase kinase (MAP3K) family. These kinases are implicated in the progression of numerous cancers by activating mitogen‐activated protein kinase (MAPK) cascades or functioning as ser/thr and tyr kinases. However, their specific roles in glioma remain elusive. In the present study, we utilized bioinformatics approaches to investigate the expression patterns of MLKs in low‐grade gliomas (LGG) and glioblastoma multiforme (GBM). Additionally, we analyzed their clinical significance and delved into the potential mechanisms underlying MLK activity as well as their association with tumor‐immune infiltrating cells (TIICs) in glioma. Furthermore, we conducted in vitro studies to elucidate the functional roles of MLK1‐2 in glioma. Our findings revealed that the expressions of MLK1‐2 were conspicuously downregulated in GBM and positively correlated with patients’ overall survival. Conversely, ZAK exhibited an opposing trend. Notably, our newly devised risk score model exhibited superior performance in predicting patient prognoses. Moreover, we analyzed the potential mechanisms of MLK activity and its interplay with tumor immune infiltration. Last, we validated the antitumor effect of MLK1‐2 at the in vitro level. In summary, our study sheds new insights into the roles of MLKs in glioma, particularly MLK1‐2, and their potential as therapeutic targets.


  • Open Access

    HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas

    by Hui Huang, Zhengyuan Huo, Jiantong Jiao, Wei Ji, Jin Huang, Zheng Bian, Bin Xu, Junfei Shao, Jun Sun

    Background: Gliomas are the most common primary malignant tumours of the central nervous system (CNS). To improve the prognosis of glioma, it is necessary to identify molecular markers that may be useful for glioma therapy. HOXC6, an important transcription factor, is involved in multiple cancers. However, the role of HOXC6 in gliomas is not clear. Methods: Bioinformatic and IHC analyses of collected samples (n = 299) were performed to detect HOXC6 expression and the correlation between HOXC6 expression and clinicopathological features of gliomas. We collected clinical information from 177 to 299 patient samples and estimated the prognostic value of HOXC6. Moreover, cell proliferation assays were performed. We performed Gene Ontology (GO) analysis and gene set enrichment analysis (GSEA) based on ChIP-seq and public datasets to explore the biological characteristics of HOXC6 in gliomas. RNA-seq was conducted to verify the relationship between HOXC6 expression levels and epithelial-mesenchymal transition (EMT) biomarkers. Furthermore, the tumour purity, stromal and immune scores were evaluated. The relationship between HOXC6 expression and infiltrating immune cell populations and immune checkpoint proteins was also researched. Results: HOXC6 was overexpressed and related to the clinicopathological features of gliomas. In addition, knockdown of HOXC6 inhibited the proliferation of glioma cells. Furthermore, increased HOXC6 expression was associated with clinical progression. The biological role of HOXC6 in gliomas was primarily associated with EMT and the immune microenvironment in gliomas. High HOXC6 expression was related to high infiltration by immune cells, a low tumour purity score, a high stromal score, a high immune score and the expression of a variety of immune checkpoint genes, including PD-L1, B7-H3 and CLTA-4. Conclusions: These results indicated that HOXC6 might be a key factor in promoting tumorigenesis and glioma progression by regulating the EMT signalling pathway and might represent a novel immune therapeutic target in gliomas.


  • Open Access

    Noncoding RNAs involved in the STAT3 pathway in glioma

    by Zheng Bian, Wei Ji, Bin Xu, Zhengyuan Huo, Hui Huang, Jin Huang, Jiantong Jiao, Junfei Shao, Xiaolu Zhang

    Glioma is the most common malignant primary brain tumour in adults. Despite improvements in neurosurgery and radiotherapy, the prognosis of glioma patients remains poor. One of the main limitations is that there are no proper clinical therapeutic targets for glioma. Therefore, it is crucial to find one or more effective targets. Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family of genes. Abnormal expression of STAT3 is involved in the process of cell proliferation, migration, invasion, immunosuppression, angiogenesis, dryness maintenance, and resistance to radiotherapy and chemotherapy in glioma. Therefore, STAT3 has been considered an ideal therapeutic target in glioma. Noncoding RNAs (ncRNAs) are a group of genes with limited or no protein-coding capacity that can regulate gene expression at the epigenetic, transcriptional and posttranscriptional level. In this review, we summarized the ncRNAs that are correlated with the ectopic expression of STAT3 in glioma.


  • A positive feedback loop of LINC00662 and STAT3 promotes malignant phenotype of glioma

    by Wei Ji, Jiantong Jiao, Chao Cheng, Yong Xiao, Junfei Shao, Hongyi Liu


  • Open Access

    Bioinformatics Analysis of Expression Profiles and Prognostic Values of the Signal Transducer and Activator of Transcription Family Genes in Glioma

    by Wei Ji, Yuankun Liu, Bin Xu, Jie Mei, Chao Cheng, Yong Xiao, Kun Yang, Weiyi Huang, Jiantong Jiao, Hongyi Liu, et al.

    Signal transducer and activator of transcription (STAT) family genes—of which there are seven members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6—have been associated with the progression of multiple cancers. However, their prognostic values in glioma remain unclear. In this study, we systematically investigated the expression, the prognostic value, and the potential mechanism of the STAT family genes in glioma. The expression of STAT1/2/3/5A/6 members were significantly higher and positively correlated with IDH mutations, while the expression of STAT5B was lower and negatively correlated with IDH mutations in glioma. Survival analysis indicated that the upregulation of STAT1/2/3/5A/6 and downregulation of STAT5B expression was associated with poorer overall survival in glioma. Joint effects analysis of STAT1/2/3/5A/5B/6 expression suggested that the prognostic value of the group was more significant than that of each individual gene. Thus, we constructed a risk score model to predict the prognosis of glioma. The receiver operating characteristic curve and calibration curves showed good performance as prognostic indicators in both TCGA (The Cancer Genome Atlas) and the CGGA (Chinese Glioma Genome Atlas) databases. Furthermore, we analyzed the correlation between STAT expression with immune infiltration in glioma. The Protein–protein interaction network and enrichment analysis showed that STAT members and co-expressed genes mainly participated in signal transduction activity, Hepatitis B, the Jak-STAT signaling pathway, transcription factor activity, sequence-specific DNA binding, and the cytokine-mediated signaling pathway in glioma. In summary, our study analyzed the expression, prognostic values, and biological roles of the STAT gene family members in glioma, based on which we developed a new risk score model to predict the prognosis of glioma more precisely.


  • Open Access

    The expression and prognostic value of the epidermal growth factor receptor family in glioma

    by Bin Xu, Zhengyuan Huo, Hui Huang, Wei Ji, Zheng Bian, Jiantong Jiao, Jun Sun, Junfei Shao

    Background: The epidermal growth factor receptor (EGFR) family belongs to the transmembrane protein receptor of the tyrosine kinase I subfamily and has 4 members: EGFR/ERBB1, ERBB2, ERBB3, and ERBB4. The EGFR family is closely related to the occurrence and development of a variety of cancers.Materials/methods: In this study, we used multiple online bioinformatics websites, including ONCOMINE, TCGA, CGGA, TIMER, cBioPortal, GeneMANIA and DAVID, to study the expression profiles, prognostic values and immune infiltration correlations of the EGFR family in glioma.Results: We found that EGFR and ERBB2 mRNA expression levels were higher in glioblastoma (GBM, WHO IV) than in other grades (WHO grade II & III), while the ERBB3 and ERBB4 mRNA expression levels were the opposite. EGFR and ERBB2 were notably downregulated in IDH mutant gliomas, while ERBB3 and ERBB4 were upregulated, which was associated with a poor prognosis. In addition, correlation analysis between EGFR family expression levels and immune infiltrating levels in glioma showed that EGFR family expression and immune infiltrating levels were significantly correlated. The PPI network of the EGFR family in glioma and enrichment analysis showed that the EGFR family and its interactors mainly participated in the regulation of cell motility, involving integrin receptors and Rho family GTPases.Conclusions: In summary, the results of this study indicate that the EGFR family members may become potential therapeutic targets and new prognostic markers for glioma.


  • Open Access

    MicroRNAs involved in the EGFR pathway in glioblastoma

    by Bin Xu, Jie Mei, Wei Ji, Zhengyuan Huo, Zheng Bian, Jiantong Jiao, Xiaoqing Li, Jun Sun, Junfei Shao


  • Open Access

    LncRNA SNHG3, a potential oncogene in human cancers

    by Bin Xu, Jie Mei, Wei Ji, Zheng Bian, Jiantong Jiao, Jun Sun, Junfei Shao

    Long noncoding RNAs (lncRNAs) are composed of > 200 nucleotides; they lack the ability to encode proteins but play important roles in a variety of human tumors. A large number of studies have shown that dysregulated expression of lncRNAs is related to tumor oncogenesis and progression. Emerging evidence shows that SNHG3 is a novel oncogenic lncRNA that is abnormally expressed in various tumors, including osteosarcoma, liver cancer, lung cancer, etc.SNHG3 primarily competes as a competitive endogenous RNA (ceRNA) that targets tumor suppressor microRNAs (miRNAs) and ceRNA mechanisms that regulate biological processes of tumors. In addition, abnormal expression of SNHG3 is significantly correlated with patient clinical features. Upregulation of SNHG3 contributes to biological functions, including tumor cell proliferation, migration, invasion and EMT. Therefore, SNHG3 may represent a potential diagnostic and prognostic biomarker, as well as a novel therapeutic target.